AACR: 21st Century Cures a “Model for An Open and Honest Conversation”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Almost one year ago (on April 30, 2014), House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), along with Oversight and Investigations Subcommittee Ranking Member Diana DeGette (D-Colo.) announced the launch of 21st Century Cures, an initiative aimed at accelerating the pace of cures and medical breakthroughs in the United States by ensuring that our laws are keeping pace with innovation.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
José Baselga
President, American Association for Cancer Research; Physician-in-chief, chief medical officer, Memorial Sloan Kettering Cancer Center
William S. Dalton
Chair, AACR Science Policy & Government Affairs Committee; chief executive officer, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

YOU MAY BE INTERESTED IN

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
For patients with an HPV-related form of throat cancer, treatment is often highly effective, with cure rates as high as 90%, depending on the disease stage. Now, researchers are investigating whether some patients can safely avoid additional treatment while maintaining excellent cancer outcomes.
José Baselga
President, American Association for Cancer Research; Physician-in-chief, chief medical officer, Memorial Sloan Kettering Cancer Center
William S. Dalton
Chair, AACR Science Policy & Government Affairs Committee; chief executive officer, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login